Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy


Epilepsy greatly affects a patient’s longevity and quality of life and has high morbidity in children. Valproic acid (VPA) has been used for more than 50 years to treat various types of seizures in children and adults [1]. In clinical practice the plasma concentration and the efficacy of VPA varies greatly between individuals [2]. Many factors such as age, body weight, total daily dose, dosage form, dosing frequency, sampling time, concomitant antiepileptic medications, diet and genetic variations involved in the pharmacokinetics of VPA are correlated with VPA plasma concentration [2–8].


Leave A Reply